Terms: = Kidney tumors AND CDKN1B, CDKN4, 1027, ENSG00000111276, MEN4, P27KIP1, P46527, MEN1B, KIP1 AND Clinical Outcome
4 results:
1. clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
Stellato M; Procopio G; De Giorgi U; Maruzzo M; Bimbatti D; Mennitto A; Sbrana A; Roviello G; Casadei C; Sepe P; Pignata S; Santini D
J Transl Med; 2021 Aug; 19(1):328. PubMed ID: 34344414
[TBL] [Abstract] [Full Text] [Related]
2. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract] [Full Text] [Related]
3. outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype.
Delahunt B; Bethwaite PB; Nacey JN
Pathology; 2007 Oct; 39(5):459-65. PubMed ID: 17886093
[TBL] [Abstract] [Full Text] [Related]
4. p27kip1-expression in human renal cell cancers: implications for clinical outcome.
Anastasiadis AG; Calvo-Sanchez D; Franke KH; Ebert T; Heydthausen M; Schulz WA; Burchardt M; Gerharz CD
Anticancer Res; 2003; 23(1A):217-21. PubMed ID: 12680216
[TBL] [Abstract] [Full Text] [Related]
